Mangoceuticals (MGRX) Institutional Ownership $4.33 -0.39 (-8.26%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$4.39 +0.06 (+1.39%) As of 02/21/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Mangoceuticals (NASDAQ:MGRX)CurrentInstitutional OwnershipPercentage56.72%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$46.38MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$2.32M Get MGRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Mangoceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data MGRX Institutional Buying and Selling by Quarter Mangoceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/12/2025 Geode Capital Management LLC12,003$29K0.0%-90.9%0.482% 2/4/2025 Ackerman Capital Advisors LLC34,500$83K0.0%-96.0%1.386% 10/24/2024 Ackerman Capital Advisors LLC873,356$206K0.1%N/A3.519% 8/8/2023 Colonial River Wealth Management LLC36,100$66K0.0%N/A0.216% 7/28/2023 Independent Advisor Alliance26,000$48K0.0%N/A0.162% (Data available from 1/1/2016 forward) MGRX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of MGRX shares? During the previous two years, the following institutional investors and hedge funds held shares of Mangoceuticals shares: Ackerman Capital Advisors LLC ($83K), Colonial River Wealth Management LLC ($66K), and Independent Advisor Alliance ($48K), Geode Capital Management LLC ($29K).Learn more on MGRX's institutional investors. What percentage of Mangoceuticals stock is owned by institutional investors? 56.72% of Mangoceuticals stock is owned by institutional investors. Learn more on MGRX's institutional investor holdings. Which institutional investors have been buying Mangoceuticals stock? The following institutional investors have purchased Mangoceuticals stock in the last 24 months: Ackerman Capital Advisors LLC ($873.36K), Colonial River Wealth Management LLC ($36.10K), and Independent Advisor Alliance ($26K). How much institutional buying is happening at Mangoceuticals? Institutional investors have bought a total of 935,456 shares in the last 24 months. This purchase volume represents approximately $71.94M in transactions. Which Mangoceuticals major shareholders have been selling company stock? The following institutional investors have sold Mangoceuticals stock in the last 24 months: Ackerman Capital Advisors LLC ($838.86K), and Geode Capital Management LLC ($119.32K). How much institutional selling is happening at Mangoceuticals? Institutional investors have sold a total of 958,180 shares in the last 24 months. This volume of shares sold represents approximately $2.32M in transactions. Related Companies ENZ Major Shareholders CCM Major Shareholders BRTX Major Shareholders OPGN Major Shareholders KDLY Major Shareholders BGLC Major Shareholders SSY Major Shareholders VSEE Major Shareholders ATIP Major Shareholders ACON Major Shareholders This page (NASDAQ:MGRX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mangoceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mangoceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
